Výsledky vyhledávání - "Edward J. Hartsough"

Akademický článek

Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma

Autor: Maria R. Cavallo, Jacob C. Yo, Kayla C. Gallant, Camille J. Cunanan, Amirali Amirfallah, Marzieh Daniali, Alyssa B. Sanders, Andrew E. Aplin, Edmund A. Pribitkin, Edward J. Hartsough

Publikováno v: Cell Death Discovery, Vol 10, Iss 1, Pp 1-13 (2024)

Abstract Papillary thyroid carcinoma (PTC) is the most frequent form of thyroid cancer. PTC commonly presents with mutations of the serine/threonine kinase BRAF (BRAFV600E), which drive ERK1/2 pathway activation to support growth and suppress apoptos

Externí odkaz: https://doaj.org/article/fd8b6b6966954f859f36cd6d1d4bbf8c

Zobrazit plný text záznamu

Akademický článek

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association

Autor: Michael J. Vido, Kaitlyn Le, Edward J. Hartsough, Andrew E. Aplin

Publikováno v: Cell Reports, Vol 25, Iss 6, Pp 1501-1510.e3 (2018)

Summary: Expression of aberrantly spliced BRAF V600E isoforms (BRAF V600E ΔEx) mediates resistance in 13%–30% of melanoma patients progressing on RAF inhibitors. BRAF V600E ΔEx confers resistance, in part, through enhanced dimerization. Here, we

Externí odkaz: https://doaj.org/article/a1e25dabd20846e7bdb84b3d8903e95d

Zobrazit plný text záznamu

Supplementary Figures 1 - 4 from Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma

Autor: Andrew E. Aplin, Kevin J. Basile, Edward J. Hartsough

PDF file - 369K, Supplemental Figure 1. PRT #3 and PRT #4 signaling analysis. Supplemental Figure 2. Invasiveness of PRT #3 and PRT #4. Supplemental Figure 3. PRT #3 and PRT #4 display an elongated, spindle-like appearance after RAF inhibitor withdra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a809f605df3144f0a7af2dc914a3e02
https://doi.org/10.1158/1541-7786.22511164

Zobrazit plný text záznamu

Supplemental Info from Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo

Autor: Andrew E. Aplin, Gideon Bollag, Karen E. Knudsen, Matthew J. Schiewer, Michael A. Davies, Allison Goldberg, Timothy J. Purwin, Adam C. Berger, Michael J. Vido, Curtis H. Kugel, Edward J. Hartsough

Supplemental Figure 1: PLX8394 does not alter CRAF or c-Src phosphorylation; Supplemental Figure 2. Treatment of xenograft-derived tumor pieces in an ex vivo explant system; Supplemental Figure 3: Patient sample extended data; Supplemental Figure 4:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f754036ede2f21641c61c659cdbc635
https://doi.org/10.1158/1535-7163.22509490

Zobrazit plný text záznamu

Data from Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo

FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K–mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells. To overcome th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0fa2f2b31c388debfefa1f6c1d3899d
https://doi.org/10.1158/1535-7163.c.6539317.v1

Zobrazit plný text záznamu

Data from Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

Autor: Andrew E. Aplin, Emad S. Alnemri, Ulrich Rodeck, Edward J. Hartsough, Adam C. Berger, Conroy O. Field, Corey Rogers, Timothy J. Purwin, Ileine M. Sanchez, Weijia Cai, Dan A. Erkes

Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAFV600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the lin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ee70b84564b7891387261da0d8155668
https://doi.org/10.1158/2159-8290.c.6547885.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání